VMVicenta Martínez-Sales

Vicenta Martínez-Sales

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vicenta Martínez-Sales has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Increased circulating endothelial cells and microparticles in patients with psoriasis

    by Vicenta Martínez-Sales, Virtudes Vila, José M. Ricart, Amparo Vayá, José Todolí, Cornelio Nńñez, Teresa Contreras, Carmén Ballester, Edelmiro Reganon

    INTRODUCTION: Psoriasis is a chronic pathology characterized by increased inflammation that can be associated with changes in the vascular endothelium. We quantified the levels of circulating endothelial cells (CECs) and microparticles (MPs) in patients with psoriasis in order to analyze their relationship with endothelial and inflammation markers, subclinical atherosclerosis and microcirculation. METHODS: We studied 20 patients and 20 controls. Circulating markers of endothelial damage (CEC, MPs and von Willebrand factor, vWF) and inflammation (E-selectin, E-sel; Interleukin-6, IL-6 and C-reactive protein, CRP) were determined. Subclinical atherosclerosis was assessed by carotid ultrasound to obtain intima-media thickness. Microcirculation was evaluated by nailfold capillaroscopy. RESULTS: CECs, MPs, vWF, CRP and E-sel levels were significantly elevated in patients when compared with controls ( p < 0.05). Ninety-four and fifty-three percentage of patients had CEC and MP levels higher than 99th percentile in controls. Forty-seven percent of patients simultaneously showed increased CEC and MP levels. MPs correlate with the inflammatory markers and with the intima-media thickness. CECs correlate with the capillaries loops per mm ( p < 0.05). CONCLUSION: Psoriasis patients show elevated CECs and MPs, as a sign of endothelial dysfunction, which correlates with inflammatory markers as well as subclinical atherosclerosis and some capillaroscopy findings.


  • C0236 Pre-analytical conditions of centrifugation and freezing but not temperature affect MP levels

    by Virtudes Vila, Silvia Navarro, Verónica Sánchez-López, Remedios Otero, Vicenta Martínez-Sales

  • C0095 Circulating endothelial cells and microparticles as prognostic markers in advanced non-small-cell lung cancer

    by Tania Fleitas, Vicenta Martínez-Sales, Virtudes Vila, Edelmiro Reganon, David Mesado, María Martín, José Gómez-Codina, Joaquín Montalar, Gaspar Reynés

  • Atorvastatin neutralises the thrombin-induced tissue factor expresion in endothelial cells via geranylgeranyl pyrophosphate

    by Vicenta Martínez-Sales, Virtudes Vila, Marcos Ferrando, Edelmiro Reganon

    Statins may have beneficial effects in atherogenesis given their antithrombotic properties involving non-lipid mechanisms that modify endothelial function of tissue factor induction by thrombin. In this study, we investigate the effect of atorvastatin on tissue factor (TF) activity in thrombin-stimulated endothelial cells and its regulation through mevalonate or its derivatives. First subculture of human umbilical endothelial cells was used for this study. Cells were treated with thrombin and atorvastatin for different time intervals and dosage. Tissue factor activity was measured as Factor Xa generation induced by Tissue Factor-Factor VIIa complex on confluent cells. Our results show that atorvastatin prevents the thrombin-induced up-regulation of tissue factor activity in a concentration-dependent manner. Mevalonate and geranylgeranyl pyrophosphate reversed this inhibitory effect of atorvastatin on tissue factor activity, while the presence of farnesyl pyrophosphate did not prevent the atorvastatin effect on thrombin-induced tissue factor activity. Rho-kinase inhibitor did not affect the thrombin stimulation of tissue factor activity. High amount of hydrophobic isoprenoid groups decreases the thrombin-induced TF activity and may promote endothelial cell anti-thrombotic action. Rho kinase pathways do not have a major role in the thrombin-mediated TF activity. The inhibitory effect of atorvastatin on thrombin-induced TF activity was partially reversed by MVA and GGPP but not FPP.


  • Atorvastatin Neutralizes the Up-Regulation of Thrombospondin-1 Induced by Thrombin in Human Umbilical Vein Endothelial Cells

    by Vicenta Martínez-Sales, Virtudes Vila, Marcos Ferrando, Edelmiro Reganon

    Statins have been reported to affect blood vessel formation. Thrombospondin-1 (TSP-1) is a multifunctional protein that affects vasculature systems such as platelet activation, angiogenesis, and wound healing. This study was designed to investigate the effect of atorvastatin on TSP-1 synthesis in thrombin-stimulated human umbilical vein endothelial cells (HUVECs), and its regulation by mevalonate or its derivatives. The results showed that atorvastatin down-regulated TSP-1 expression in HUVECs. This effect was fully reversed by mevalonate, farnesylpyrophosphate (FPP), and gerarylgeranylpyrophosphate (GGPP). Furthermore, farnesyltransferase and geranylgeranyltransferase inhibitors decreased TSP-1expression. It was also found that thrombin increased TSP-1 expression in HUVECs. Atorvastatin (0.1, 1, and 10 μM) decreased TSP-1 in thrombin-stimulated cells (45%, 66%, and 80%). Mevalonate partially reversed this inhibitory effect of atorvastatin on TSP-1, whereas the presence of FPP and GGPP did not alter TSP-1. Rho-kinase inhibitor neutralized the up-regulation of TSP-1 induced by thrombin. In conclusion, atorvastatin inhibits TSP-1 expression in endothelial cells via the mevalonate pathway. Rho protein activation is necessary for up-regulation of TSP-1 synthesis induced by thrombin. Because FPP and GGPP are essential for the activity of Rho proteins, inhibition of these proteins may constitute the mechanism by which atorvastatin inhibits thrombin up-regulated TSP-1 expression.


    • 1 July 2004
      • Vol. 92  (1) , 223-4

    Erythrocyte aggregation and -455G/A polymorphism of the beta-fibrinogen gene in survivors of acute myocardial infarction.

    by Amparo Vayá, Silvia Breña, Edelmiro Réganon, Virtudes Vila, Vicenta Martinez-Sales, Maria Teresa Contreras, Esther Zorio, Dolores Corella, Justo Aznar

  • Erythrocyte aggregation and −455G/A polymorphism of the β-fibrinogen gene in survivors of acute myocardial infarction

    by Silvia Breña, Edelmiro Réganon, Virtudes Vila, Vicenta Martínez-Sales, Maria Teresa Contreras, Esther Zorio, Dolores Corella, Justo Aznar, Amparo Vayá


    • 1 June 2003
      • Vol. 88  (6) , 694-9

    Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.

    by Vicenta Martinez-Sales, Virtudes Vila, Edelmiro Réganon, Javier Garcia Oms, Justo Aznar

    Unfractionated heparin and low molecular weight heparins exert their anticoagulant effect by mobilizing tissue factor pathway inhibitor (TFPI) from the vascular endothelium into the blood circulation. We compared the influence of unfractionated heparin and enoxaparin on the anticoagulant function of cultured human endothelial cells. Monolayers of human umbilical vein endothelial cells were treated with 10 U/mL unfractionated heparin or enoxaparin for different periods of time (30min-48h). Endothelial cell procoagulant activity was determined in the cell lysates by a chromogenic assay. Endothelial cell tissue factor (TF) and released TFPI and von Willebrand factor (vWF) was determined. In short periods of incubation (30min-2h), both heparins reduced endothelial cell procoagulant activity, the inhibition produced by unfractionated heparin being greater than that induced by enoxaparin (p<0.05). However, no variations were observed in TFPI and vWF release. With long periods of incubation (24-48h), both unfractionated heparin and enoxaparin significantly increased TFPI release (control vs. unfractionated heparin, p<0.05-0.001; control vs. enoxaparin, p<0.01-0.001) and also reduced the release of vWF in the culture medium, though no variations in endothelial cell procoagulant activity or TF content were observed. Our findings show that unfractionated heparin and enoxaparin exert different kinds of effects on endothelial cells. With short incubation periods, procoagulant endothelial cell capacity was reduced to a greater extent by unfractionated heparin, while after longer periods of incubation enoxapain increased the anticoagulant activity of the endothelial cells to a greater degree than did unfractionated heparin.


    • 1 July 2002
      • Vol. 87  (7) , 740

    Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction.

    by Edelmiro Réganon, Virtudes Vila, Vicenta Martínez-Sales, Amparo Vaya, Justo Aznar

    It has been reported that the influence of plasma fibrinogen on the incidence of myocardial infarction is related to inflammatory processes. The aim of this study was to investigate the relationship between inflammatory activity, fibrinogen and thrombin generation in patients 5 years after the acute phase of myocardial infarction. Sixty-seven patients 5 years after a myocardial infarction and 67 control subjects were studied. Plasma fibrinogen protein (Fg-protein) and function (Fg-function), prothrombin fragment 1+2 (F1+2), thrombin-antithrombin complex (TAT), total sialic acid (TSA) and C-reactive protein (CRP) were measured. The levels of Fg-protein, Fg-function, F1+2, TAT, TSA and CRP were significantly higher in patients than in the control subjects. Plasma TSA correlated with CRP (r=0.31, p<0.05). There was a significant correlation between TSA and Fg-protein or Fg-function (r=0.48, p<0.01). CRP correlated with Fg-function (r=0.32, p<0.05) while there was no correlation between CRP and Fg-protein. CRP also correlated with F1+2 and TAT (r= 0.4, p<0.01). Five years after myocardial infarction there was clear evidence of low-grade inflammation that was accompanied by an increase in thrombin formation. The increase of the plasma fibrinogen level is mainly related to TSA and the increase of CRP, which is associated with thrombin generation.